Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

Trial Details

NCT ID
NCT05739981
Phase
PHASE1 / PHASE2
Sponsor
Imunon
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Paclitaxel
  • Carboplatin
  • Bevacizumab
  • IMNN-001
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • New York, New York, United States|40.71427,-74.00597
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Subjects with ovarian, fallopian tube, or primary peritoneal carcinoma with high grade serous adenocarcinoma histology are eligible. Poorly differe…
  • Subjects must have an International Federation of Gynecology and Obstetrics (FIGO) stage of III or IV who based on standard of care clinical consid…
  • Subjects must have adequate: bone marrow function, renal function, hepatic function, and neurologic function.
  • Subjects should be free of active infection requiring isolation, parenteral antibiotics or a serious uncontrolled medical illness or disorder withi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →